Previous 10 | Next 10 |
San Francisco, California--(Newsfile Corp. - April 7, 2022) - Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses to submit your losses now . The firm is investigating possible violations of the securities laws. Visit: www.hbsslaw.com/investor-fraud...
Natera Publishes VALID Study Results for Prospera Lung dd-cfDNA Transplant Rejection Assessment Test PR Newswire AUSTIN, Texas , April 7, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the ...
Natera Adds to Organ Health Medical Affairs Leadership Team PR Newswire Sangeeta Bhorade , M.D., appointed as head of organ health medical affairs AUSTIN, Texas , April 6, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-f...
Natera Announces Publication Highlighting Importance of Testing Total cfDNA when Monitoring Kidney Transplant Patients with COVID-19 Infection PR Newswire AUSTIN, Texas , April 1, 2022 /PRNewswire/ -- Natera , Inc. (NASDAQ: NTRA), a global leader ...
Natera Listed as One of World's Most Innovative Health Companies by Fast Company PR Newswire Company recognized for its ability to monitor therapy response with its Signatera™ MRD test AUSTIN, Texas , March 28, 2022 /PRNewswire/ -- Nate...
About a third of biotech companies will have one year of cash or less by the end of 2022, the Morgan Stanley analysts led by Matthew Harrison said this week based on a sample of 380 firms. While the number of companies requiring cash is similar to the levels seen before 2018 – 21, the ...
GNOM lacks efficient portfolio reshuffling and may not be able to gain from higher alpha-producing stocks in the near future. Despite being a ‘Genomic Revolution’ fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better ‘...
SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers...
New Data in Simultaneous Pancreas-Kidney Transplantation Further Demonstrates the Value of Prospera dd-cfDNA Technology PR Newswire Biopsy-matched study assesses pancreas rejection in the context of a simultaneous kidney-pancreas transplant AUSTIN, Texas ...
Natera Inc. (NASDAQ:NTRA) was named a new best idea at Piper Sandler as the firm sees a "modest, if any" impact on Natera's P&L from matters talked about in the Hindenburg short report. Piper Sandler spoke to a "key opinion leader" on Friday who said the short report likely "grossly embel...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...